[go: up one dir, main page]

WO2009105629A3 - Methods for the treatment and prevention of necrotizing enterocolitis - Google Patents

Methods for the treatment and prevention of necrotizing enterocolitis Download PDF

Info

Publication number
WO2009105629A3
WO2009105629A3 PCT/US2009/034660 US2009034660W WO2009105629A3 WO 2009105629 A3 WO2009105629 A3 WO 2009105629A3 US 2009034660 W US2009034660 W US 2009034660W WO 2009105629 A3 WO2009105629 A3 WO 2009105629A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
prevention
treatment
methods
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/034660
Other languages
French (fr)
Other versions
WO2009105629A2 (en
Inventor
Akhil Maheshawari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of WO2009105629A2 publication Critical patent/WO2009105629A2/en
Publication of WO2009105629A3 publication Critical patent/WO2009105629A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides for the administration of TGF-? or a TGF-? derivative to treat and/or prevent a variety of disease states and/or conditions, characterized by the cytokine response of immature intestinal epithelial cells to mucosal injury, bacterial invasion, bacterial antigens and/or products, including, but not limited to, NEC. Furthermore, the present disclosure provides for a pharmaceutical composition and medicaments comprising a therapeutically effective amount of TGF-? or a TGF-? derivative for use in the methods described herein.
PCT/US2009/034660 2008-02-20 2009-02-20 Methods for the treatment and prevention of necrotizing enterocolitis Ceased WO2009105629A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2993608P 2008-02-20 2008-02-20
US61/029,936 2008-02-20

Publications (2)

Publication Number Publication Date
WO2009105629A2 WO2009105629A2 (en) 2009-08-27
WO2009105629A3 true WO2009105629A3 (en) 2009-11-26

Family

ID=40986201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/034660 Ceased WO2009105629A2 (en) 2008-02-20 2009-02-20 Methods for the treatment and prevention of necrotizing enterocolitis

Country Status (1)

Country Link
WO (1) WO2009105629A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018621A1 (en) * 2012-07-24 2014-01-30 The Board Of Trustees Of The University Of Illinois Method of predicting necrotizing enterocolitis
US9186379B2 (en) * 2013-02-23 2015-11-17 Stemnion, Inc. Methods for preventing or treating necrotizing enterocolitis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLAUD ERIKA C. ET AL.: "Modulation of Human Intestinal Epithelial Cell IL-8 Secretion by Human Milk Factors", PEDIATRIC RESEARCH, vol. 53, no. 3, 2003, pages 419 - 425 *
DATABASE NCBI 18 November 2007 (2007-11-18), Database accession no. NP003229 *
MAREK ANDRZEJ ET AL.: "Human milk, a multipotent infant's immune system fortifier", MED SCI MONIT, vol. 9, no. SUP.4, 2003, pages 75 - 81 *
URUAKPA F.O. ET AL.: "Colostrum and its benefits: a review", NUTRITION RESEARCH, vol. 22, 2002, pages 755 - 767 *

Also Published As

Publication number Publication date
WO2009105629A2 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2009051837A3 (en) Vaccine nanotechnology
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
MX2015005798A (en) Combination therapy.
HK1218560A1 (en) Compositions and methods
WO2008083174A3 (en) Compositions and methods for the treatment of infections and tumors
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
MY168763A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
WO2012022478A3 (en) Filler composition comprising beta-glucans
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2013166177A3 (en) Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
AR093182A1 (en) METHOD TO TREAT OVERWEIGHT OR OBESITY
WO2012177653A3 (en) Targeting the neuromuscular junction for treatment
EP4464375A3 (en) Methods of treatment using single doses of oritavancin
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
WO2012158405A3 (en) Compositions and methods for the treatment of skin diseases
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2011076208A3 (en) Calcipotriol monohydrate nanocrystals
WO2009151714A3 (en) Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
WO2009105629A3 (en) Methods for the treatment and prevention of necrotizing enterocolitis
CA2863829A1 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2008036733A3 (en) Methods for treatment of vesicle transport disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09712752

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09712752

Country of ref document: EP

Kind code of ref document: A2